- Home
- EYPT vs TTI Comparison
EYPT vs TTI Comparison
Compare EYPT & TTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EYPT | TTI |
|---|---|---|
| Founded | 1987 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Oil & Gas Production |
| Sector | Industrials | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2005 | 1990 |
Fundamental Metrics
Financial Performance| Metric | EYPT | TTI |
|---|---|---|
| Price | $15.19 | $11.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $28.75 | $10.40 |
| AVG Volume (30 Days) | 907.6K | ★ 2.2M |
| Earning Date | 03-04-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7085.43 |
| EPS | N/A | ★ 0.92 |
| Revenue | $42,339,000.00 | ★ $618,755,000.00 |
| Revenue This Year | N/A | $5.43 |
| Revenue Next Year | N/A | $4.18 |
| P/E Ratio | ★ N/A | $13.01 |
| Revenue Growth | N/A | ★ 0.17 |
| 52 Week Low | $3.91 | $2.03 |
| 52 Week High | $19.11 | $12.25 |
Technical Indicators
Market Signals| Indicator | EYPT | TTI |
|---|---|---|
| Relative Strength Index (RSI) | 42.44 | 60.29 |
| Support Level | $14.62 | $10.70 |
| Resistance Level | $16.73 | $12.25 |
| Average True Range (ATR) | 1.03 | 0.63 |
| MACD | -0.16 | 0.01 |
| Stochastic Oscillator | 21.30 | 64.61 |
Price Performance
Historical ComparisonAbout EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
About TTI Tetra Technologies Inc.
Tetra Technologies Inc is a diversified oil and gas services company, focused on completion fluids and associated products and services, water management, frac flowback, production well testing, offshore rig cooling, and compression services. It has two reporting segments namely Completion Fluids & Products, and Water & Flowback Services. The Completion Fluids & Products Division manufactures and markets clear brine fluids, additives, and associated products and services. Majority of revenue is from Completion Fluids & Products. The company derives maximum revenue from United states.